Clinical Trials at Drexel Gastroenterology
Previous Clinical Studies
The REVERSE Clnical Study will evaluate the effects of obeticholic acid in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
The Drexel Center for Liver, Biliary and Pancreatic Diseases is running a clinical study to evaluate the effects of obeticholic acid (OCA) on improvement in nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease.
Drexel Gastroenterology & Hepatology is running a clinical study evaluating the use of terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1.
The Resolve-IT clinical trial will evaluate the efficacy of elafibranor on the resolution of nonalcoholic steatohepatitis (NASH), a form of nonalcoholic fatty liver disease.
The information on these pages is provided for general information only and should not be used for diagnosis or treatment, or as a substitute for consultation with a physician or health care professional. If you have specific questions or concerns about your health, you should consult your health care professional.